FLONASE ALLERGY RELIEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLONASE ALLERGY RELIEF (FLONASE ALLERGY RELIEF).
Glucocorticoid agonist; binds to glucocorticoid receptors, inhibiting inflammatory mediators (e.g., cytokines, prostaglandins) and reducing nasal mucosal inflammation.
| Metabolism | Hepatic via CYP3A4 to active metabolite fluticasone propionate; also hydrolyzed by esterases. |
| Excretion | Primarily hepatic metabolism via CYP3A4; renal excretion accounts for <5% as unchanged drug, with the remainder as metabolites in feces (approximately 90%) and urine (approximately 5%). |
| Half-life | Terminal elimination half-life is approximately 10 hours (range 7–14 hours), reflecting slow release from tissue binding sites; accumulation occurs with once-daily dosing, achieving steady state in 1–2 weeks. |
| Protein binding | Approximately 91% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent volume of distribution is approximately 4.2 L/kg (range 2.5–6.5 L/kg), indicating extensive tissue distribution and sequestration in lipid-rich compartments. |
| Bioavailability | Intranasal: Absolute bioavailability is <1% due to extensive first-pass hepatic metabolism and low systemic absorption; systemic exposure is minimal at recommended doses. |
| Onset of Action | Intranasal: Symptom relief begins within 12 hours after the first dose, with maximum effect observed after several days of regular use. |
| Duration of Action | Duration of action is approximately 24 hours with once-daily dosing; continuous use is required for sustained relief of allergic rhinitis symptoms. |
2 sprays (50 mcg each) per nostril once daily, total daily dose 200 mcg. If inadequate, may increase to 2 sprays per nostril twice daily (400 mcg/day).
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; caution in severe hepatic impairment as systemic bioavailability may increase. |
| Pediatric use | Aged 4-11 years: 1 spray (50 mcg) per nostril once daily (100 mcg/day). Aged 12 years and older: same as adult. |
| Geriatric use | No specific dose adjustment; use same as adult dosing with monitoring for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLONASE ALLERGY RELIEF (FLONASE ALLERGY RELIEF).
| Breastfeeding | Fluticasone propionate is excreted in human breast milk in very low concentrations. The M/P ratio is not established due to minimal systemic absorption after intranasal use. It is unlikely to cause adverse effects in the breastfed infant at recommended doses. Caution is advised, but fluticasone is considered compatible with breastfeeding. |
| Teratogenic Risk | Fluticasone propionate (FLONASE ALLERGY RELIEF) is an intranasal corticosteroid. In animal studies, high systemic doses caused teratogenic effects, but intranasal administration yields minimal systemic absorption. No increased risk of major malformations has been observed in human studies with inhaled or intranasal corticosteroids. First trimester: No evidence of significant risk; second and third trimesters: No increased risk of fetal harm; however, chronic high-dose systemic corticosteroids are associated with intrauterine growth restriction and adrenal suppression. Overall, intranasal fluticasone is considered low risk in pregnancy. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component of the product"]
| Precautions | ["Nasal septum perforation","Localized Candida infections","Growth suppression in children","HPA axis suppression with prolonged high doses","Hypersensitivity reactions (e.g., urticaria, anaphylaxis)","Ocular effects (e.g., glaucoma, cataracts)"] |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring is required for intranasal fluticasone use. However, if used for prolonged periods or at higher than recommended doses, consider monitoring maternal adrenal function. For pregnant women, standard prenatal care is sufficient. |
| Fertility Effects | No known adverse effects on human fertility. In animal studies, high systemic doses caused reduced fertility, but intranasal fluticasone exhibits minimal systemic absorption. At recommended intranasal doses, no impact on fertility is expected. |